A new analysis published in Medicine suggests that long-term reliance on glucocorticoids poses a significant health and economic burden on adults with generalized myasthenia gravis (MG) in the United States.
Glucocorticoids remain a cornerstone of treatment for MG, but prolonged use is associated with well-known complications, including infections and heart problems, as well as high healthcare costs. The new retrospective study examined patterns of glucocorticoid use and related outcomes among commercially insured U.S. adults living with MG.
Researchers examined medical and pharmacy claims to assess steroid exposure, treatment patterns, healthcare utilization and steroid-related complications. The study found that many patients with MG were prescribed glucocorticoid therapy for extended periods of time and frequently received moderate-to-high daily doses. This level of exposure was associated with substantial rates of steroid-related adverse events, including metabolic, cardiovascular, bone and infection-related complications.
Learn more about MG treatment and care
The research also found that those using higher doses of steroids tended to require more healthcare overall, including more outpatient visits, hospitalizations and pharmacy claims. These findings reinforce earlier research showing that people with MG often experience significant healthcare costs, particularly when disease control remains challenging.
The study’s authors say the results highlight a continuing challenge in treating generalized MG and point to an ongoing need for treatments that can control the disease while reducing reliance on chronic steroid therapy.
“There is an unmet need for effective disease-modifying treatments to mitigate GC exposure for improved gMG management and patient outcomes,” they concluded. “The introduction of effective alternative treatment options with more favorable safety profiles may help to alleviate the adverse clinical and economic impacts of elevated GC use among patients with gMG.”
Sign up here to get the latest news, perspectives, and information about MG sent directly to your inbox. Registration is free and only takes a minute.
